Andrographis paniculata - A multicentric, randomized, double-blind homoeopathic pathogenetic trial

Authors

Rajpal Rajpal, Central Council for Research in Homoeopathy, New Delhi
Vinay Singh, Central Council for Research in Homoeopathy, New Delhi
B Dutta, Drug Proving Research Unit (H), Kolkata, West Bengal
S Das, Drug Proving Research Unit (H), Kolkata, West Bengal
P Mal, Drug Proving Research Unit (H), Midnapore, West Bengal
A Bhakat, Drug Proving Research Unit (H), Midnapore, West BengalDrug Proving Research Unit (H), Midnapore, West Bengal
R Roy, Drug Proving Research Unit (H), Ghaziabad, Uttar Pradesh
C Chaudhary, Drug Proving Research Unit (H), Ghaziabad, Uttar Pradesh

Keywords

homoeopathy; pathogenetic effect; homoeopathic pathogenetic trial; drug proving; Andrographis paniculata

Article Type

Original Article

Abstract

Objective: To elicit the pathogenetic response of the drug Andrographis paniculata in homoeopathic potencies on healthy human beings. Methodology: Drug Andrographis paniculata was proved by the Central Council for Research in Homoeopathy through double-blind, randomized, placebo-controlled method. The study was conducted at three centers. The drug was proved in two potencies (6C and 30C) on 39 apparently healthy volunteers who were selected after conducting pre-trial medical examination by the medical specialists and routine laboratory investigations. In the first phase volunteers were given 56 doses (04 doses per day for 14 days) of placebo. In the next two phases 56 doses (04 doses per day for 14 days) of each potency or placebo were consumed. The symptoms generated during the trial period were noted by the volunteers and elaborated by the Proving Masters. The data obtained from all the three centers was compiled at proving-cum-data processing cell at CCRH headquarters after de-coding. Observations: Out of the 23 provers who were on actual drug trial, 06 manifested symptoms. Drug was able to produce symptoms in both the potencies more or less related to every part of the body. Some of the symptoms have been reproved which are mentioned in different literatures after the fragmentary proving. Conclusion: New and reproved pathogenetic responses elicited during the proving trial expands the scope of use of the drug Andrographis paniculata and will benefit the research scholars and clinicians. These symptoms will carry more value when verified clinically.

Digital Object Identifier

10.53945/2320-7094.1715

Publisher

Wolters Kluwer India Pvt. Ltd.

How to cite this article

Rajpal R, Singh V, Dutta B, et al. Andrographis paniculata - A multicentric, randomized, double-blind homoeopathic pathogenetic trial. Indian J Res Homoeopathy 2011;5:9-14. doi: 10.53945/2320-7094.1715